[go: up one dir, main page]

MXPA02011858A - Inhibidores de adhesion de celula mediada por alfabeta2. - Google Patents

Inhibidores de adhesion de celula mediada por alfabeta2.

Info

Publication number
MXPA02011858A
MXPA02011858A MXPA02011858A MXPA02011858A MXPA02011858A MX PA02011858 A MXPA02011858 A MX PA02011858A MX PA02011858 A MXPA02011858 A MX PA02011858A MX PA02011858 A MXPA02011858 A MX PA02011858A MX PA02011858 A MXPA02011858 A MX PA02011858A
Authority
MX
Mexico
Prior art keywords
cell adhesion
mediated cell
inhibitors
beta
alpha
Prior art date
Application number
MXPA02011858A
Other languages
English (en)
Inventor
Paul S Furth
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of MXPA02011858A publication Critical patent/MXPA02011858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente0020invencion se refiere a moleculas pequenas de acuerdo con l a formula (I) que son potentes inhibidores de adhesion de celula mediada por a???2 y que pueden ser utiles para el tratamiento de enfermedades inflamatorias. (ver formula).
MXPA02011858A 2000-05-31 2001-04-17 Inhibidores de adhesion de celula mediada por alfabeta2. MXPA02011858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20796800P 2000-05-31 2000-05-31
PCT/US2001/012323 WO2001092253A2 (en) 2000-05-31 2001-04-17 Inhibitors of alpha l beta 2 mediated cell adhesion

Publications (1)

Publication Number Publication Date
MXPA02011858A true MXPA02011858A (es) 2004-07-30

Family

ID=22772705

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011858A MXPA02011858A (es) 2000-05-31 2001-04-17 Inhibidores de adhesion de celula mediada por alfabeta2.

Country Status (18)

Country Link
US (1) US6699888B2 (es)
EP (1) EP1284973B1 (es)
JP (1) JP3924531B2 (es)
KR (1) KR100527290B1 (es)
CN (1) CN1209358C (es)
AT (1) ATE365729T1 (es)
AU (2) AU2001253538B2 (es)
BR (1) BR0111188A (es)
CA (1) CA2411671C (es)
CY (1) CY1106843T1 (es)
DE (1) DE60129132T2 (es)
DK (1) DK1284973T3 (es)
ES (1) ES2284641T3 (es)
IL (1) IL152961A0 (es)
MX (1) MXPA02011858A (es)
NZ (1) NZ522852A (es)
PT (1) PT1284973E (es)
WO (1) WO2001092253A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492035A1 (en) 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2006082834A1 (ja) * 2005-02-02 2006-08-10 Kowa Co., Ltd. ケラチノサイト増殖に起因する疾患の予防・治療剤
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN101454002B (zh) * 2006-03-27 2011-06-08 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
KR20160027254A (ko) 2006-03-29 2016-03-09 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
JP5535925B2 (ja) * 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2787083C (en) 2010-02-16 2018-05-22 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US6350763B1 (en) * 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease

Also Published As

Publication number Publication date
AU2001253538B2 (en) 2004-03-04
WO2001092253A3 (en) 2002-05-23
DE60129132D1 (de) 2007-08-09
CY1106843T1 (el) 2012-05-23
HK1051370A1 (en) 2003-08-01
US20030225138A1 (en) 2003-12-04
JP2003535087A (ja) 2003-11-25
DK1284973T3 (da) 2007-10-08
PT1284973E (pt) 2007-08-17
EP1284973B1 (en) 2007-06-27
KR100527290B1 (ko) 2005-11-09
CA2411671A1 (en) 2001-12-06
CN1432007A (zh) 2003-07-23
JP3924531B2 (ja) 2007-06-06
ES2284641T3 (es) 2007-11-16
CA2411671C (en) 2007-06-05
CN1209358C (zh) 2005-07-06
EP1284973A2 (en) 2003-02-26
ATE365729T1 (de) 2007-07-15
US6699888B2 (en) 2004-03-02
DE60129132T2 (de) 2008-02-28
IL152961A0 (en) 2003-06-24
KR20030015235A (ko) 2003-02-20
BR0111188A (pt) 2003-06-10
NZ522852A (en) 2004-09-24
WO2001092253A2 (en) 2001-12-06
AU5353801A (en) 2001-12-11

Similar Documents

Publication Publication Date Title
MXPA02011858A (es) Inhibidores de adhesion de celula mediada por alfabeta2.
DE69824037D1 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
MY135856A (en) Nicotinamide derivatives useful as pde4 inhibitors
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
ATE318841T1 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BG105880A (en) Compounds useful as anti-inflammatory agents
YU4403A (sh) Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta
DE60213407D1 (de) Zusammensetzungen zur hemmung der angiogenese
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
PL350786A1 (en) Cell adhesion−inhibiting antiinflammatory and immune−suppressive compounds
AU2002358390A1 (en) Novel compounds
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
TW200505865A (en) Compounds useful for the treatment of diseases
YU47100A (sh) Novi derivati dihidroksiheksanoinske kiseline
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
SE0302756D0 (sv) Novel Compounds
TW200407133A (en) Novel PPARα and PPARγ agonists
MY128261A (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration